Limits...
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.

Jhund PS, Fu M, Bayram E, Chen CH, Negrusz-Kawecka M, Rosenthal A, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M, PARADIGM-HF Investigators and Committe - Eur. Heart J. (2015)

Bottom Line: The findings for HFH were similar for CV and all-cause mortality and the age category by treatment interactions were not significant.The pre-specified safety outcomes of hypotension, renal impairment and hyperkalaemia increased in both treatment groups with age, although the differences between treatment (more hypotension but less renal impairment and hyperkalaemia with LCZ696) were consistent across age categories.LCZ696 was more beneficial than enalapril across the spectrum of age in PARADIGM-HF with a favourable benefit-risk profile in all age groups.

View Article: PubMed Central - PubMed

Affiliation: BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK.

No MeSH data available.


Related in: MedlinePlus

Proportion of patients with a five-point or greater fall (deterioration) in Kansas City Cardiomyopathy Questionnaire at 8 months by age category and treatment.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4595742&req=5

EHV330F3: Proportion of patients with a five-point or greater fall (deterioration) in Kansas City Cardiomyopathy Questionnaire at 8 months by age category and treatment.

Mentions: The proportion of patients with a fall in KCCQ score of five points or more (i.e. a clinically meaningful deterioration) was smaller in those treated with LCZ696 compared with patients treated with enalapril, as shown in Figure 3. This benefit of LCZ696 over enalapril in preventing worsening of KCCQ was consistent across the age groups (P-value for interaction = 0.90). The interaction was still not statistically significant after adjusting for differences in baseline characteristics (P for interaction = 0.67). We also found no interaction between age, treatment, and region on KCCQ score (P for interaction = 0.44).Figure 3


Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.

Jhund PS, Fu M, Bayram E, Chen CH, Negrusz-Kawecka M, Rosenthal A, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M, PARADIGM-HF Investigators and Committe - Eur. Heart J. (2015)

Proportion of patients with a five-point or greater fall (deterioration) in Kansas City Cardiomyopathy Questionnaire at 8 months by age category and treatment.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4595742&req=5

EHV330F3: Proportion of patients with a five-point or greater fall (deterioration) in Kansas City Cardiomyopathy Questionnaire at 8 months by age category and treatment.
Mentions: The proportion of patients with a fall in KCCQ score of five points or more (i.e. a clinically meaningful deterioration) was smaller in those treated with LCZ696 compared with patients treated with enalapril, as shown in Figure 3. This benefit of LCZ696 over enalapril in preventing worsening of KCCQ was consistent across the age groups (P-value for interaction = 0.90). The interaction was still not statistically significant after adjusting for differences in baseline characteristics (P for interaction = 0.67). We also found no interaction between age, treatment, and region on KCCQ score (P for interaction = 0.44).Figure 3

Bottom Line: The findings for HFH were similar for CV and all-cause mortality and the age category by treatment interactions were not significant.The pre-specified safety outcomes of hypotension, renal impairment and hyperkalaemia increased in both treatment groups with age, although the differences between treatment (more hypotension but less renal impairment and hyperkalaemia with LCZ696) were consistent across age categories.LCZ696 was more beneficial than enalapril across the spectrum of age in PARADIGM-HF with a favourable benefit-risk profile in all age groups.

View Article: PubMed Central - PubMed

Affiliation: BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK.

No MeSH data available.


Related in: MedlinePlus